Table 1.
Patients-characteristics
| Sex | Age | Histology | WHO performance status | Staging | Metastases | Previous treatment | Treatment (duration of CTX) | Steroid | Clinical response |
|---|---|---|---|---|---|---|---|---|---|
| M | 62 | Colon adenocarcinoma | 1 | IV | Lung, liver | FolFox, FolFiri irinotecan Cetuximab | CTX cetuximab (2 months) | Yes | PD |
| M | 65 | Clear cell renal carcinoma | 2 | IV | Peritoneal carcinomatosis | 5FU cisplatin | CTX | No | PD |
| M | 37 | Gastric adenocarcinoma | 1 | IV | Bone, lung, liver | ECF FolFiri | CTX | No | PD |
| F | 48 | Rectal adenocarcinoma | 2 | IV | Peritoneal carcinomatosis, liver, lung | FolFox, FolFiri irinotecan cetuximab | CTX cetuximab (2 months) | No | SD 2 months |
| M | 58 | Pleural mesothelioma | 1 | IV | Lung, mediastinal nodes | Imatinib | CTX imatinib (2 months) | No | SD 3 months |
| F | 61 | Clear cell ovarian cancer | 1 | IV | Peritoneal carcinomatosis | Taxol carboplatin gemcitabin | CTX (2 months) | Yes | SD 3 months |
| M | 37 | Melanoma | 2 | IV | Peritoneal carcinomatosis | Dacarbazin, fortemustine | CTX | No | ND |
| M | 52 | Sarcoma | 1 | IV | Liver | Imatinib | CTX imatinib (2 months) | No | SD 2 months |
| F | 45 | Clear cell renal carcinoma | 1 | IV | Lung, liver | Interferon | CTX | Yes | ND |
PD progressive disease, SD stable disease, ND not determined, M male, F female, CTX cyclophosphamide, 5FU 5 fluorouracil, FolFox 5 FU + oxaliplatin, FolFiri 5FU + irinotecan, ECF epirubicin + cisplatin + 5FU